公开(公告)号：US08795975B2

公开(公告)日：2014-08-05

申请号：US13990393

申请日：2011-11-25

申请人： William D. Arnold ,  Christelle Jost ,  Brian Noland ,  Jonathan Gary ,  Joseph Buechler ,  Vance Wong ,  Scott Harold Rongey ,  Uday Kumar Veeramallu ,  Kelline Marie Rodems

发明人： William D. Arnold ,  Christelle Jost ,  Brian Noland ,  Jonathan Gary ,  Joseph Buechler ,  Vance Wong ,  Scott Harold Rongey ,  Uday Kumar Veeramallu ,  Kelline Marie Rodems

IPC分类号： G01N31/00 ,  G01N33/53

CPC分类号： G01N33/6893 ,  G01N2800/325 ,  G01N2800/60

摘要： The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.

摘要翻译： 本发明部分地涉及诊断心力衰竭的发生，特别是在表现出利钠肽的正常体液水平的受试者中。 本发明还部分地涉及将受试者的结局风险（例如恶化心脏功能或死亡风险，再住院风险）分配给患者。 所述方法包括进行一种或多种测定，所述测定法检测在从受试者获得的体液样品上进行的选自由WAP4C，ESAM，LTBR，间皮素和Syndecan-1组成的组中的一种或多种生物标志物，以及分配诊断或风险， 至少部分地取决于由此获得的结果。

公开(公告)号：US20140147867A1

公开(公告)日：2014-05-29

申请号：US13990393

申请日：2011-11-25

申请人： William D. Arnold ,  Christelle Jost ,  Brian Noland ,  Jonathan Gary ,  Joseph Buechler ,  Vance Wong ,  Scott Harold Rongey ,  Uday Kumar Veeramallu ,  Kelline Marie Rodems

发明人： William D. Arnold ,  Christelle Jost ,  Brian Noland ,  Jonathan Gary ,  Joseph Buechler ,  Vance Wong ,  Scott Harold Rongey ,  Uday Kumar Veeramallu ,  Kelline Marie Rodems

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2800/325 ,  G01N2800/60

摘要： The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.

摘要翻译： 本发明部分地涉及诊断心力衰竭的发生，特别是在表现出利钠肽的正常体液水平的受试者中。 本发明还部分地涉及将受试者的结局风险（例如恶化心脏功能或死亡风险，再住院风险）分配给患者。 所述方法包括进行一种或多种测定，所述测定法检测在从受试者获得的体液样品上进行的选自由WAP4C，ESAM，LTBR，间皮素和Syndecan-1组成的组中的一种或多种生物标志物，以及分配诊断或风险， 至少部分地取决于由此获得的结果。

公开(公告)号：US20140315734A1

公开(公告)日：2014-10-23

申请号：US14130209

申请日：2012-07-03

申请人： William D. Arnold ,  Christelle Jost ,  Brian Noland ,  Jonathan Gary ,  Joseph Buechler ,  Vance Wong ,  Scott Harold Rongey ,  Uday Kumar Veeramallu ,  Kelline Marie Rodems

发明人： William D. Arnold ,  Christelle Jost ,  Brian Noland ,  Jonathan Gary ,  Joseph Buechler ,  Vance Wong ,  Scott Harold Rongey ,  Uday Kumar Veeramallu ,  Kelline Marie Rodems

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2800/347 ,  G01N2800/52

摘要： The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject.

摘要翻译： 本发明包括在心脏或肾衰竭的情况下的诊断和预后，特别是在表现出利尿钠肽的正常体液水平的受试者中。 本发明还涉及分配具有AKI的受试者对AKI进展敏感的增加的可能性的方法。 本发明部分地涉及至少部分地基于对受试者的心脏和/或肾衰竭的诊断和/或结局风险（例如，恶化的心脏和/或肾脏功能或死亡风险）的分配。 从检测从受试者获得的体液样品上进行的检测WAP四硫化物核域结构蛋白2的测定获得的结果。